Nuchev Limited logo

Nuchev Limited (NUC)

Market Closed
ASX ASX
- Market Cap
- P/E Ratio
- Div Yield
2,880 Volume
-0.07 Eps
Want to track NUC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

NUC is not paying dividends to its shareholders.
The last earnings report, released on Feb 25, 2026, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -0.0067%, based on the last three reports.
Nuchev Limited has completed 2 stock splits, with the recent split occurring on May 19, 2023.
The company's stock is traded on one exchange.

Nuchev Limited (NUC) FAQ

On which exchange is it traded?

Nuchev Limited is listed on ASX.

What is its stock symbol?

The ticker symbol is NUC.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Nuchev Limited ever had a stock split?

Nuchev Limited had 2 splits and the recent split was on May 19, 2023.

Nuchev Limited Profile

Health Care Equipment & Supplies Industry
Healthcare Sector
Oded Bashan CEO
ASX Exchange
Q6S83Q101 CUSIP
IL Country
3 Employees
- Last Dividend
19 May 2023 Last Split
- IPO Date

Overview

IR-Med Inc. operates as a development stage medical device company, with a primary focus on creating non-invasive devices tailored for various medical needs. Situated in Rosh Pina, Israel, the company commits itself to innovation in the medical field, aiming to enhance patient care and diagnostic procedures using cutting-edge technology. Their mission is evident in the development of devices like PressureSafe and Nobiotics, which represent significant advancements in medical diagnostics and patient care, especially in areas that have traditionally relied on invasive methods or extensive wait times for results.

Products and Services

  • PressureSafe:
  • A revolutionary handheld optical monitoring device from IR-Med Inc., PressureSafe is designed to aid in the early detection of pressure injuries to the skin and underlying tissue. These injuries are primarily caused by prolonged pressure, often associated with bed confinement, making this device particularly useful in clinical settings where patients are at risk of developing such conditions. Its non-invasive nature not only allows for quicker assessments but also significantly reduces the discomfort associated with traditional methods of detection.

  • Nobiotics:
  • The Nobiotics otoscope is another innovative device by IR-Med Inc., engineered to assist physicians by providing immediate indications of mid-ear infections, a common ailment particularly in children. This tool simplifies and speeds up the diagnosis process, potentially improving outcomes by facilitating quicker treatment strategies. Its design and functionality highlight IR-Med Inc.'s dedication to enhancing diagnostic procedures, reducing the strain on both medical professionals and patients, and paving the way for more efficient and effective healthcare solutions.

Contact Information

Address: ZHR Industrial Zone
Phone: 972 4 655 5054